AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10683055 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (100 mg/wk intramuscularly), no exercise
Number of subjects: 61
Study 10683055 — intervention group
Group type: COMPARATOR
Intervention: Placebo, no exercise
Number of subjects: 61
Study 10683055 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo and exercise
Number of subjects: 61
Study 10683055 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone and exercise
Number of subjects: 61
Study 9596916 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-insertion group
Number of subjects: 910
Study 9596916 — intervention group
Group type: COMPARATOR
Intervention: Ring forceps-insertion group
Number of subjects: 910
Study 8151563 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminobenzoate potassium (KPAB) 12 g/day
Number of subjects: 146
Study 8151563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 3277606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc administration
Number of subjects: 151
Study 3277606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 29900614 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Training Group (PTG)
Number of subjects: 31
Study 29900614 — intervention group
Group type: COMPARATOR
Intervention: No Training Group (NTG)
Number of subjects: 31
Study 28782571 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-person perspective visualisation
Number of subjects: 0
Study 28782571 — intervention group
Group type: COMPARATOR
Intervention: First-person perspective visualisation
Number of subjects: 0
Study 26270340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) at 0.1 mg/kg/day, target 5‐8 ng/ml
Number of subjects: 141
Study 26270340 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin A (CSA) with target 70‐150 ng/ml
Number of subjects: 141
Study 23571174 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 bivalent vaccine
Number of subjects: 0
Study 23571174 — intervention group
Group type: COMPARATOR
Intervention: Control group (no new infection with HPV31/45/58)
Number of subjects: 0
Study 21415807 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Restoration Program (FRP)
Number of subjects: 132
Study 21415807 — intervention group
Group type: COMPARATOR
Intervention: Active Individual Therapy (Control)
Number of subjects: 132
Study 18457236 — intervention group
Group type: EXPERIMENTAL
Intervention: EsCIT + CBTI
Number of subjects: 30
Study 18457236 — intervention group
Group type: COMPARATOR
Intervention: EsCIT + CTRL
Number of subjects: 30
Study 16566934 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum müllerian-inhibiting substance (MIS) levels in patients with OHSS
Number of subjects: 30
Study 16566934 — intervention group
Group type: COMPARATOR
Intervention: Baseline serum müllerian-inhibiting substance (MIS) levels in normal controls
Number of subjects: 30
Study 12715267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d
Number of subjects: 320
Study 12715267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/d
Number of subjects: 320
Study 12715267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 10714093 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomyocardial biopsy specimens from patients with DCMP
Number of subjects: 6
Study 10714093 — intervention group
Group type: COMPARATOR
Intervention: Negative controls from myocardial specimens of two persons who died in motor vehicle accidents
Number of subjects: 6
Study 9180319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-band osteosynthesis
Number of subjects: 40
Study 9180319 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 40
Study 1489187 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg clarithromycin
Number of subjects: 39
Study 1489187 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg clarithromycin
Number of subjects: 39
Study 1489187 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg clarithromycin
Number of subjects: 39
Study 1489187 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clarithromycin
Number of subjects: 39
Study 1489187 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg clarithromycin
Number of subjects: 39
Study 1489187 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg clarithromycin
Number of subjects: 39
Study 1489187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3735223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 125 mg tds for three days
Number of subjects: 96
Study 3735223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 125 mg tds for seven days
Number of subjects: 96
Study 29292092 — intervention group
Group type: EXPERIMENTAL
Intervention: KB001-A
Number of subjects: 182
Study 29292092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 27814258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment (1 W, 10 Hz for 60 seconds, unfocused at 0.5 cm distance)
Number of subjects: 23
Study 27814258 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAlAs laser treatment (40 mW; 4 J/cm²; 15 seconds per point on 4 points)
Number of subjects: 23
Study 27814258 — intervention group
Group type: COMPARATOR
Intervention: 2% neutral fluoride gel application (60 seconds)
Number of subjects: 23
Study 27814258 — intervention group
Group type: COMPARATOR
Intervention: Sham treatments
Number of subjects: 23
Study 24452706 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted arm group therapy (RAGT) + individual arm therapy (IAT) for 30 minutes each, per workday for four weeks.
Number of subjects: 50
Study 24452706 — intervention group
Group type: COMPARATOR
Intervention: Individual arm therapy (IAT) for 2x30 minutes, per workday for four weeks.
Number of subjects: 50
Study 24452706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of treatment with RAGT.
Number of subjects: 50
Study 23709633 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HF-rTMS stimulation
Number of subjects: 50
Study 23709633 — intervention group
Group type: COMPARATOR
Intervention: Sham HF-rTMS stimulation
Number of subjects: 50
Study 19945508 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 24 (24 trials of stimulation)
Number of subjects: 24
Study 19945508 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 36 (36 trials of stimulation)
Number of subjects: 24
Study 19945508 — intervention group
Group type: COMPARATOR
Intervention: Control group (without stimulation)
Number of subjects: 24
Study 18425236 — intervention group
Group type: COMPARATOR
Intervention: High-fiber diet (approximately 30 g)
Number of subjects: 64
Study 18425236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet plus 10 g of hydrolyzed partially guar-gum
Number of subjects: 64
Study 16171472 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-catheterisation group
Number of subjects: 262
Study 16171472 — intervention group
Group type: COMPARATOR
Intervention: Catheterisation group
Number of subjects: 262
Study 13678871 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg once daily)
Number of subjects: 3023
Study 13678871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3023
Study 13678871 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 3023
Study 10582548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet with one daily fish meal (3.6 g omega3 fatty acids per day)
Number of subjects: 55
Study 10582548 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise training (55% to 65% maximal oxygen consumption [VO2max])
Number of subjects: 55
Study 10582548 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exercise training (heart rate <100 bpm)
Number of subjects: 55
Study 10582548 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet alone
Number of subjects: 55
Study 8947318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet light detection of urinary riboflavin tracer
Number of subjects: 38
Study 8947318 — intervention group
Group type: COMPARATOR
Intervention: Placebo group in clinical trials of medications for alcoholism treatment
Number of subjects: 38
Study 1880222 — intervention group
Group type: EXPERIMENTAL
Intervention: Volmax (4 mg) administered after a meal
Number of subjects: 24
Study 1880222 — intervention group
Group type: EXPERIMENTAL
Intervention: Proventil Repetabs (4 mg) administered after a meal
Number of subjects: 24
Study 1880222 — intervention group
Group type: COMPARATOR
Intervention: Volmax (4 mg) administered in fasting state
Number of subjects: 24
Study 1880222 — intervention group
Group type: COMPARATOR
Intervention: Proventil Repetabs (4 mg) administered in fasting state
Number of subjects: 24
Study 6852412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg orally and intravenously)
Number of subjects: 22
Study 31763269 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-counter normal saline
Number of subjects: 0
Study 31763269 — intervention group
Group type: COMPARATOR
Intervention: Nasal decongestant drops
Number of subjects: 0
Study 31763269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal drops (only)
Number of subjects: 0
Study 28027123 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% FiO2
Number of subjects: 177
Study 28027123 — intervention group
Group type: COMPARATOR
Intervention: 30% FiO2
Number of subjects: 177
Study 25644148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant in combination with conventional 5HT3 blocker-based prophylaxis
Number of subjects: 41
Study 25644148 — intervention group
Group type: COMPARATOR
Intervention: Control arm (conventional 5HT3 blocker-based prophylaxis only)
Number of subjects: 41
Study 25644148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 41
Study 24325574 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control failure
Number of subjects: 214
Study 24325574 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-awareness
Number of subjects: 214
Study 24325574 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 214
Study 21956278 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic treatment
Number of subjects: 130
Study 21956278 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy + Basic treatment
Number of subjects: 130
Study 21956278 — intervention group
Group type: COMPARATOR
Intervention: Control group (Healthy gingiva)
Number of subjects: 130
Study 19902479 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery using three arms
Number of subjects: 109
Study 19902479 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 109
Study 19902479 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 109
Study 17969890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pabing Recipe 1 (PR1) plus Madopa tablets
Number of subjects: 101
Study 17969890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pabing Recipe 3 (PR3) plus Madopa tablets
Number of subjects: 101
Study 17969890 — intervention group
Group type: COMPARATOR
Intervention: Fixed Chinese recipe plus Madopa tablets
Number of subjects: 101
Study 15889658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Plus with AdheSE
Number of subjects: 105
Study 15889658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Plus with Xeno III
Number of subjects: 105
Study 15889658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Plus with Clearfil SEBond
Number of subjects: 105
Study 15889658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Plus with Unifil Bond
Number of subjects: 105
Study 15889658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Plus with experimental self-etching bonding system (Xeno III and SE Bond)
Number of subjects: 105
Study 15889658 — intervention group
Group type: COMPARATOR
Intervention: Fuji Plus with conditioner (10% ferric chloride, 2% citric acid solution)
Number of subjects: 105
Study 15889658 — intervention group
Group type: COMPARATOR
Intervention: SuperBond
Number of subjects: 105
Study 11958301 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-balance ultrafiltration (ZBUF)
Number of subjects: 30
Study 11958301 — intervention group
Group type: COMPARATOR
Intervention: Control (no ultrafiltration)
Number of subjects: 30
Study 9972143 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (LDD)
Number of subjects: 0
Study 9972143 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 7644243 — intervention group
Group type: EXPERIMENTAL
Intervention: NE-21610 (0.3, 3.0, 10 micrograms)
Number of subjects: 31
Study 7644243 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 31
Study 7644243 — intervention group
Group type: EXPERIMENTAL
Intervention: NE-21610 (100 micrograms, s.c.)
Number of subjects: 31
Study 7644243 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (s.c. control)
Number of subjects: 31
Study 2651472 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (25 mg twice daily for 4 days) + PGE2 (1 mg once or twice)
Number of subjects: 42
Study 2651472 — intervention group
Group type: COMPARATOR
Intervention: RU 486 (25 mg twice daily for 4 days) + Placebo
Number of subjects: 42
Study 342679 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme tablets (mutanase and protease)
Number of subjects: 40
Study 342679 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 40
Study 31568024 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% rAOP
Number of subjects: 23
Study 31568024 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% eAOP
Number of subjects: 23
Study 31568024 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% to 80% rAOP
Number of subjects: 23
Study 31568024 — intervention group
Group type: EXPERIMENTAL
Intervention: eAOP
Number of subjects: 23
Study 30762663 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Intervention (CBI)
Number of subjects: 72
Study 30762663 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (information about pain)
Number of subjects: 72
Study 30762663 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 72
Study 30762663 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between tDCS and CBI
Number of subjects: 72
Study 27606825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0
Study 27606825 — intervention group
Group type: COMPARATOR
Intervention: Sugar placebo
Number of subjects: 0
Study 25767256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir
Number of subjects: 1797
Study 25767256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir
Number of subjects: 1797
Study 25767256 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir
Number of subjects: 1797
Study 23503548 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 53
Study 23503548 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 53
Study 23503548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (VPA)
Number of subjects: 53
Study 23503548 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 53
Study 21626572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (CPT) immediately
Number of subjects: 60
Study 21626572 — intervention group
Group type: COMPARATOR
Intervention: Cognitive processing therapy (CPT) after 10 weeks
Number of subjects: 60
Study 20095196 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond burs
Number of subjects: 60
Study 20095196 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐glaze
Number of subjects: 60
Study 20095196 — intervention group
Group type: EXPERIMENTAL
Intervention: Overglaze
Number of subjects: 60
Study 20095196 — intervention group
Group type: EXPERIMENTAL
Intervention: Reglaze
Number of subjects: 60
Study 20095196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pearl Surface polishing system
Number of subjects: 60
Study 20095196 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond Twist SCL
Number of subjects: 60
Study 16691031 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (n = 41)
Number of subjects: 82
Study 16691031 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 41)
Number of subjects: 82
Study 16691031 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 82
Study 16691031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 15310546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyst evacuation plus PEI (50 to 70% of cystic fluid extracted)
Number of subjects: 281
Study 15310546 — intervention group
Group type: COMPARATOR
Intervention: Simple cyst evacuation
Number of subjects: 281
Study 15310546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyst evacuation plus PEI
Number of subjects: 281
Study 11781766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed treatment incorporating both group and individualized treatment
Number of subjects: 31
Study 11781766 — intervention group
Group type: COMPARATOR
Intervention: Group treatment only
Number of subjects: 31
Study 9403648 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented premature formula
Number of subjects: 68
Study 9403648 — intervention group
Group type: COMPARATOR
Intervention: Premature formula alone (Control)
Number of subjects: 68
Study 8509313 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (320 mg, three tablets every six hours)
Number of subjects: 8
Study 8509313 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical schedule as aspirin)
Number of subjects: 8
Study 8509313 — intervention group
Group type: COMPARATOR
Intervention: Post-test condition (one week after testing in the first two conditions)
Number of subjects: 8
Study 8509313 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and placebo (double-blind administration)
Number of subjects: 8
Study 3542984 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 99
Study 3542984 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 99
Study 30045179 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan nerve tube in primary nerve repair
Number of subjects: 74
Study 30045179 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical nerve repair alone (Control)
Number of subjects: 74
Study 27119579 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR164653 (20 to 800 mg single oral doses, repeat doses up to 800 mg)
Number of subjects: 0
Study 27119579 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR164653 (single dosing)
Number of subjects: 0
Study 27119579 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR164653 (multiple dosing)
Number of subjects: 0
Study 27119579 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR164653
Number of subjects: 0
Study 24476560 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary School Free Breakfast Initiative
Number of subjects: 4500
Study 24476560 — intervention group
Group type: COMPARATOR
Intervention: Control (wait-list)
Number of subjects: 4500
Study 23147343 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 29
Study 23147343 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 29
Study 20465172 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial width-to-height ratio
Number of subjects: 0
Study 20465172 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally neutral faces varying in perceived threat
Number of subjects: 0
Study 18538928 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal suggestion alone (Group 1)
Number of subjects: 44
Study 18538928 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning procedure (Group 2)
Number of subjects: 44
Study 18538928 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 44
Study 16613888 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (LAH)
Number of subjects: 0
Study 16613888 — intervention group
Group type: COMPARATOR
Intervention: Control (no assisted hatching)
Number of subjects: 0
Study 14622313 — intervention group
Group type: EXPERIMENTAL
Intervention: High impedance ventricular leads
Number of subjects: 40
Study 14622313 — intervention group
Group type: COMPARATOR
Intervention: Standard impedance ventricular leads
Number of subjects: 40
Study 11085757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention including provision of information, coping skills training, and parent coaching
Number of subjects: 40
Study 11085757 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 9002829 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implants (subcrestal placement, polished surface sunk by 1 mm)
Number of subjects: 11
Study 9002829 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implants (subcrestal placement)
Number of subjects: 11
Study 9002829 — intervention group
Group type: COMPARATOR
Intervention: Control implants (placed at alveolar crest)
Number of subjects: 11
Study 9002829 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implants
Number of subjects: 11
Study 9002829 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified gingival index at 4 months (test implants)
Number of subjects: 11
Study 1335003 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated essential hypertensives
Number of subjects: 0
Study 1335003 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated essential hypertensives (propranolol therapy)
Number of subjects: 0
Study 1335003 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree blood relatives of essential hypertensives
Number of subjects: 0
Study 1335003 — intervention group
Group type: COMPARATOR
Intervention: Normotensive control subjects
Number of subjects: 0
Study 6704507 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide administered as a solution
Number of subjects: 0
Study 6704507 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide administered as a tablet
Number of subjects: 0
Study 31145817 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-hybrid simulator (REAL)
Number of subjects: 27